We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

279 hedge funds and large institutions have $12.7B invested in Ascendis Pharma A/S in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 99 increasing their positions, 92 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

216% more call options, than puts

Call options by funds: $124M | Put options by funds: $39.3M

155% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 22

17% more capital invested

Capital invested by funds: $10.9B → $12.7B (+$1.83B)

13% more funds holding

Funds holding: 247 → 279 (+32)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

8% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 92

0.65% more ownership

Funds ownership: 102.88% → 103.53% (+0.65%)

Holders
279
Holders Change
+32
Holders Change %
+12.96%
% of All Funds
3.66%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.22%
New
56
Increased
99
Reduced
92
Closed
22
Calls
$124M
Puts
$39.3M
Net Calls
+$84.9M
Net Calls Change
+$58.3M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$164M
2
Principal Financial Group
Principal Financial Group
Iowa
+$143M
3
VPC
Vestal Point Capital
New York
+$74.6M
4
SCM
Spyglass Capital Management
California
+$72.5M
5
Macquarie Group
Macquarie Group
Australia
+$36M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$171M
2
Citadel Advisors
Citadel Advisors
Florida
-$104M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$79.3M
4
Artisan Partners
Artisan Partners
Wisconsin
-$50.3M
5
WP
Woodline Partners
California
-$37.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
26
Macquarie Group
Australia
$61.5M +$36M +192,804 +165%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$58.9M +$794K +4,256 +1%
JP Morgan Chase
28
JP Morgan Chase
New York
$58.1M +$15.7M +84,255 +40%
Qube Research & Technologies (QRT)
29
Qube Research & Technologies (QRT)
United Kingdom
$57.7M +$16.6M +89,128 +44%
BNP Paribas Financial Markets
30
BNP Paribas Financial Markets
France
$47.4M +$13.6M +72,864 +44%
SL
31
Siren LLC
Connecticut
$46.9M -$1.88M -10,081 -4%
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$46.6M -$5.38M -28,870 -11%
RSCM
33
Rock Springs Capital Management
Maryland
$42.6M -$466K -2,500 -1%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$41.6M +$17.1M +91,682 +78%
Victory Capital Management
35
Victory Capital Management
Texas
$41.5M -$1.9M -10,187 -5%
SEI Investments
36
SEI Investments
Pennsylvania
$40.8M -$5.83M -31,251 -13%
Allspring Global Investments
37
Allspring Global Investments
North Carolina
$39.1M -$1.6M -8,585 -4%
UBS Group
38
UBS Group
Switzerland
$38.8M +$21M +112,444 +136%
O
39
OrbiMed
New York
$38.2M +$29.4M +157,505 +458%
BNP Paribas Asset Management
40
BNP Paribas Asset Management
France
$37.7M -$16.3M -87,330 -32%
Two Sigma Investments
41
Two Sigma Investments
New York
$36.6M +$33.7M +180,771 +5,803%
DCM
42
Driehaus Capital Management
Illinois
$35.6M -$2.97M -15,940 -8%
CS
43
Candriam SCA
Luxembourg
$35.6M -$3.01M -16,159 -8%
AIP
44
ARS Investment Partners
New York
$34.9M -$6.39M -34,263 -16%
TLP
45
Tri Locum Partners
New York
$34.8M +$5.07M +27,187 +18%
Millennium Management
46
Millennium Management
New York
$34.7M +$19M +101,715 +140%
FAM
47
Fred Alger Management
New York
$33.9M +$31.1M +166,906 +4,398%
QGA
48
Q Global Advisors
Texas
$33.8M -$15.9M -85,000 -33%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$33.8M -$2.36M -12,664 -7%
RCAP
50
Resolute Capital Asset Partners
Colorado
$32.9M +$933K +5,000 +3%
1
2
3 4 5

ASND Hedge Fund Activity: Q3 2025 in Review

279 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2025, worth a combined $12.7B — up 17% from $10.9B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new ASND positions and 22 closed out — a net gain of 34 holders — while 99 added to existing stakes and 92 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $164M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $171M.

  • 279 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2025, up from 247 in Q2 2025.
  • Funds reported $12.7B of Ascendis Pharma A/S stock for Q3 2025, up 17% quarter-over-quarter.
  • 56 funds opened new Ascendis Pharma A/S positions in Q3 2025 and 22 closed out, a net change of +34 holders.
  • The largest Ascendis Pharma A/S buyer in Q3 2025 was Wellington Management Group, an estimated $164M added.
  • The largest Ascendis Pharma A/S seller in Q3 2025 was T. Rowe Price Investment Management, an estimated $171M sold.

Based on aggregated 13F filings for Q3 2025.